Progression of renal disease: New insights into risk factors and pathomechanisms

Current Opinion in Nephrology and Hypertension

Volumn 13, Issue 3, 2004, Pages 307-312

  Gross, Marie Luise ^a   Amann, Kerstin ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Endothelin; Nephron underdosing; Obesity; Smoking; Sympathetic nervous system

Indexed keywords

SEX HORMONE;

ADRENERGIC SYSTEM; CLINICAL FEATURE; DISEASE COURSE; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY STRUCTURE; MEDICAL RESEARCH; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE; RISK FACTORS;

EID: 2342557182     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200405000-00007     Document Type: Review

References (64)

1. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37:720-727.
2. Hillege HL, Fidler V, Diercks GF, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 108:1777-1782.
3. Pinto-Sietsma SJ, Navis G, Janssen WM, et al. PREVEND Study Group. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003; 41:733-741.
4. Pi-Sunyer X. A clinical view of the obesity problem. Science 2003; 299:859-860.
5. Wolf G. After all those fat years: renal consequences of obesity. Nephrol Dial Transplant 2003; 18:2471-2474. This excellent paper reviews recent insights into the role of obesity as a renal risk factor, with particular emphasis on the role of leptin.
6. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL; PREVEND study group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26 (Suppl 4):S21-S24.
7. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59:1498-1509.
8. Morales E, Valero MA, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319-327.
9. Cummings DE, Schwartz MW. Genetics and pathophysiology of human obesity. Annu Rev Med 2003; 54:453-471.
10. Wolf G, Chen, S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002; 39:1-11.
11. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int 1999; 56:860-872.
12. Janssen U, Riley SG, Vassiliadou A, et al. Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int 2003; 63:2162-2170. This is the first report to show that hyperglycemia per se sensitizes the kidney to subsequent injury from hypertension or inflammation.
13. Gross ML, Ritz E, Schoof A, et al. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003; 83:1267-1277.
14. Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens 2002; 11:483-488.
15. Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington county, Maryland. J Am Soc Nephrol 2003; 14:2934-2941.
16. Briganti EM, Branley P, Chadban SJ, et al. Smoking is associated with renal impairment and proteinuria in the normal population: the AusDiab kidney study. Australian Diabetes, Obesity and Lifestyle Study. Am J Kidney Dis 2002; 40:704-712.
17. Lhotta K, Rumpelt HJ, Konig P, et al. Cigarette smoking and vascular pathology in renal biopsies. Kidney Int 2002; 61:648-654.
18. Silbiger SR, Neugarten J. The role of gender in the progression of renal disease. Adv Ren Replace Ther 2003; 10:3-14. Comprehensive review of experimental and clinical data on an important role of gender in the progression of renal disease.
19. Coggins CH, Breyer Lewis J, Caggiula AW, et al. Differences between women and men with chronic renal disease. Nephrol Dial Transplant 1998; 13:1430-1437.
20. Negulescu O, Bognar I, Lei J, et al. Estradiol reverses TGF-beta1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism. Kidney Int 2002; 62:1989-1998.
21. Guccione M, Silbiger S, Lei J, Neugarten J. Estradiol upregulates mesangial cell MMP-2 activity via the transcription factor AP-2. Am J Physiol Renal Physiol 2002; 282:F164-F169.
22. Sandberg K, Ji H. Sex and the renin angiotensin system: implications for gender differences in the progression of kidney disease. Adv Ren Replace Ther 2003; 10:15-23. This review examines the hypothesis that modulation of the activity of the RAS by sex steroids markedly contributes to the gender differences observed in the pathophysiology of progressive kidney disease.
23. Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 2002; 110:1753-1758.
24. Keller G, Zimmer G, Mall G, et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348:101-108. This is an autopsy study documenting the fact that there are approximately 50% fewer nephrons in Caucasian patients with essential hypertension than in normotensive control patients matched for age and sex.
25. Ingelfinger JR. Is microanatomy destiny? N Engl J Med 2003; 348:99-100.
26. Hoy WE, Rees M, Kile E, et al. A new dimension to the Barker hypothesis: low birthweight and susceptibility to renal disease. Kidney Int 1999; 56:1072-1077.
27. Hughson M, Farris AB 3rd, Douglas-Denton R, et al. Glomerular number and size in autopsy kidneys: the relationship to birth weight. Kidney Int 2003; 63:2113-2122. This important study documents, for the first time in humans, a direct correlation between birth weight and nephron number.
28. Vehaskari VM, Aviles DH, Manning J. Prenatal programming of adult hypertension in the rat. Kidney Int 2001; 59:238-245.
29. Woods LL, Ingelfinger JR, Nyengaard JR, Rasch R. Maternal protein restriction suppresses the newborn renin-angiotensin system and programs adult hypertension in rats. Pediatr Res 2001; 49:460-467.
30. Moritz KM, Dodic M, Wintour EM. Kidney development and the fetal programming of adult disease. Bioessays 2003; 25:212-220. This is an excellent and timely review on nephron development and fetal programming.
31. Wintour EM, Moritz KM, Johnson K, et al. Reduced nephron number in adult sheep, hypertensive as a result of prenatal glucocorticoid treatment. J Physiol 2003; 549:929-935.
32. Culen-McEwen LA, Kett MM, Dowling J, et al. Nephron number, renal function, and arterial pressure in aged GDNF heterozygous mice. Hypertension 2003; 41:335-340. This paper presents evidence that loss of one glial cell line-derived neurotrophic growth factor allele in mice leads to a 25% lower nephron number and subsequent hypertension in adulthood.
33. Moritz KM, Wintour EM, Dodic M. Fetal uninephrectomy leads to postnatal hypertension and compromised renal function. Hypertension 2002; 39:1071-1076.
34. Ruggenenti P, Perna A, Remuzzi G, on behalf of the Investigators of the Gisen Group. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63:2254-2261.
35. Gross ML, Hanke W, Koch A, et al. Intraperitoneal protein injection in the axolotl: the amphibian kidney as a novel model to study tubulointerstitial activation. Kidney Int 2002; 62:51-59.
36. Arima S, Kohagura K, Xu HL, et al. Non-genomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14:2255-2283. This paper draws attention to the non-genomic renal effects of aldosterone, i.e. an elevation in renal vascular resistance and glomerular capillary pressure.
37. Kellner M, Peiter A, Hafner M, et al. Early aldosterone up-regulated genes: new pathways for renal disease? Kidney Int 2003; 64:1199-1207.
38. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003; 5:408-417.
39. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal falure: a wake-up call. J Am Soc Nephrol 2004; 15:524-537. Very comprehensive review of recent experimental and clinical insights into the pathomechanisms of sympathetic hyperactivity in renal failure.
40. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol 2003; 81:607-621.
41. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15:717-724.
42. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
43. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13:170-176.
44. Vonend O, Oberhauser V, von Kugelgen I, et al. ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int 2002; 61:1617-1626.
45. Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21:1709-1717.
46. Klein IH, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430. Sympathetic hyperactivity in patients with renal failure is lowered by angiotensin-converting enzyme inhibitors and angiotenein II blockade, indicating that mechanisms mediated by angiotensin II are involved.
47. Pinto-Sietsma SJ, Herrmann SM, Schmidt-Petersen K, et al. Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic population. J Am Soc Nephrol 2003; 14:2598-2602.
48. Sorokin A, Kohan DE. Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 2003; 285:F579-F589.
49. Wilasrusmee C, Da Silva M, Siddiqui J, et al. Role of endothelin-1 in microvascular dysfunction caused by cyclosporin A. J Am Coll Surg 2003; 196:584-591.
50. Lal MA, Brismar H, Eklof AC, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002; 61:2006-2014.
51. -/- mice documenting the fact that renal failure, and even uninephrectomy, upregulates endothelial markers of oxidative stress, leading to accelerated atherosclerosis.
52. Satoh M, Yamasaki Y, Nagake Y, et al. Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 2001; 59:1943-1950.
53. Eckardt KU, Rosenberger C, Jurgensen JS, Wiesener MS. Role of hypoxia in the pathogenesis of renal disease. Blood Purif 2003; 21:253-257. This is an excellent review on a potential role of hypoxia and hypoxia-mediated genes in various renal diseases.
54. Bahlmann FH, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64:1648-1652. Recombinant human erythropoietin increased the number of functionally active endothelial progenitor cells by differentiation in vitro in a dose-dependent manner. This finding may open up new therapeutic strategies in regenerative cardiovascular medicine.
55. Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003; 14 (Suppl 2):S173-S177.
56. Rossert JA, McClellan WM, Roger SD, et al. Contribution of anaemia to progression of renal disease: a debate. Nephrol Dial Transplant 2002; 17 (Suppl 1):60-86.
57. Wagner J. Nuclear (receptor) power: retinoids in rat mesangioproliferative disease. Nephrol Dial Transplant 2002; 17 (Suppl 9):81-83.
58. Schaier M, Jocks T, Gröne HJ, et al. Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol 2003; 170:1398-1402.
59. Kiss E, Adams J, Gröne HJ, Wagner J. Isotretinoin ameliorates renal damage in experimental acute renal allograft rejection. Transplantation 2003; 76:480-489.
60. Liebler S, Uberschar B, Kubert H, et al. The renal retinoid system: time-dependent activation in experimental glomerulonephritis. Am J Physiol Renal Physiol 2004; 286:F458-F465; Epub 2003 Oct 28.
61. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-dihydroxyvitamin D decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286:F528-F533; Epub 2003 Nov 4.
62. Fogo AB. Regression lines in chronic kidney disease. J Am Soc Nephrol 2003; 14:2990-2991.
63. Boffa JJ, Lu Y, Placier S, et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14:1132-1144.
64. Adamczak M, Gross ML, Krtil J, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14:2833-2842.